Mr. Robbie Lawlor:

Research shows that between 2011 and 2016 there were over 100 cases of compulsory licensing being issued globally. Some 81 of those have been approved and of the 19 that have not been, the majority have resulted in the reduction of the prices, whether through voluntary licensing or through negotiations between pharma and the countries involved.